Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of the fixed-dose combination of insulin degludec and the glucagon-like peptide-I receptor agonist (GLP-1 RA), liraglutide (IDegLira) in the treatment of type 2 diabetes mellitus (T2DM). Data Sources: A PubMed and MEDLINE search (1966 to July 2017) of the keywords insulin degludec, liraglutide, and type 2 diabetes mellitus was conducted. References were reviewed to identify additional citations. Study Selection and Data Extraction: Articles written in English were included if they evaluated the pharmacokinetics, pharmacology, clinical efficacy, or safety of IDegLira in humans. Data Synthesis: IDegLira displayed pharmacokinetic and pharmacodynamic properties similar to that of the individual components. IDegLira has shown significant hemoglobin A1C (A1C) reductions of 1.3% to 1.9% and fasting plasma glucose reductions of 45 to 65 mg/dL when used in patients with T2DM previously receiving oral antihyperglycemic agents (AHAs), GLP-1 RAs, or basal insulin. Weight loss also occurred when IDegLira was started in patients previously receiving oral AHAs or basal insulin. Adverse effects (AEs) tended to be mild and transient. The most common AEs were headache, nasopharyngitis, upper-respiratory infections, and gastrointestinal disorders. Hypoglycemia risk was lower with IDegLira than basal insulin alone but higher than liraglutide alone. Conclusions: IDegLira may provide additional glycemic control with fewer AEs for patients uncontrolled on a GLP-RA or basal insulin alone. Additional studies evaluating use in patients on oral AHAs with higher A1C values and in comparison to bolus insulin are needed.
Introduction
Type 2 diabetes mellitus (T2DM) is a complex disease, affecting an estimated 29 million American adults, 25% of whom are undiagnosed. 1 Recently, paradigms related to classification and treatment of diabetes have been evolving. In 2009, DeFronzo 2 highlighted the need to address 8 core defects of diabetes ("the ominous octet") in a comprehensive therapeutic approach. Subsequently, a new β-centric model expanded the number of pathological targets from 8 to 11; the culmination of genetic and environmental insults ("the egregious eleven") converge, resulting in or relating to the dysfunction of β-cells and hyperglycemia. 3 With the emergence of new classes of antihyperglycemic agents (AHAs) showing promising results in outcomes studies, [4] [5] [6] updated diabetes management guidelines have begun emphasizing the importance of achieving glycemic goals while using therapies with complementary mechanisms of action, beneficial weight profiles, and the potential to prevent associated microvascular and macrovascular complications. 7, 8 Optimal therapeutic strategies should use a patient-individualized regimen, targeting as many of the hyperglycemic pathways with the fewest agents and adverse effects (AEs). 3, 8 Metformin remains a favorable choice when taking these recommendations into account because it has demonstrated a decrease in diabetes-related microvascular and macrovascular complications. [7] [8] [9] Whereas metformin remains the standard of care for initial pharmacotherapy management, adjunct agents can complement this medication and therapeutic lifestyle changes to address additional disease pathways. 3 Metformin addresses 4 of the 11 pathways: insulin resistance in the liver, muscle, and adipose tissue and abnormalities of the gut biome. 3 Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are appealing as adjunct AHAs because they target 7 of the 11 identified pathways of hyperglycemia. Like metformin, incretin mimetic agents are theorized to target gut microbiota abnormalities while adding targets associated with pancreatic functioning (β-cell, α-cell, and incretin effects) and addressing dysregulation in various organs or body systems (brain, stomach and small intestine, and immune system). 3 The eleventh pathway, which relates to renal glucose reabsorption, at present can be treated only with the sodium-glucose transport protein 2 inhibitors. 3 GLP-1 RAs have several beneficial secondary effects in patients with diabetes because they can reduce weight and blood pressure; some agents within the class, including the long-acting, once-daily liraglutide, have demonstrated positive outcomes related to cardiovascular disease and mortality in patients with diabetes. 4, 5 In light of these effects, GLP-1 RAs are among the preferred second-line or add-on agents in the 2017 American Association of Clinical Endocrinologists (AACE) guideline algorithm when metformin and lifestyle changes alone are insufficient. 8 In patients who fail metformin monotherapy, the American Diabetes Association (ADA) recommends an individualized approach for adjunct therapy without suggesting a hierarchy. 7 Also, in patients uncontrolled on basal insulin, they suggest adding either mealtime insulin, a GLP-1 RA, or a conversion to mixed insulin for postprandial glucose lowering, again, without suggesting one approach over the other. 7 Insulin therapy is often necessary to reach glycemic targets and address insulin deficiency associated with β-cell dysfunction but does not address multiple core defects. Despite the capacity to significantly lower hemoglobin A1C (A1C), insulin therapy has several drawbacks, including weight gain, hypoglycemia, cost, and potentially, multiple daily injections. Combining insulin with agents that improve its optimal utilization physiologically may minimize these disadvantages.
Several formulations combining more than 1 AHA are available on the market; oral combination products and mixed insulin preparations have been used for several years in diabetes management. Recently, 2 products combining basal insulin with a GLP-1 RA were approved by the Food and Drug Administration (FDA). IGlarLixi combines insulin glargine with the newly approved short-acting, once-daily GLP-1 RA, lixisenatide. IDegLira, is a combination of insulin degludec and liraglutide. When adding one of these agents to metformin, 10 of 11 hyperglycemia pathways described above are addressed. 3 This article will specifically explore the safety, efficacy, and potential place in therapy of IDegLira.
Data Sources
PubMed and MEDLINE (1966 to July 2017) were searched using insulin degludec, liraglutide, and type 2 diabetes as keywords. The reference lists of identified articles were also reviewed for pertinent citations. Clinical trials written in English, involving human subjects, and with complete data on clinical outcomes were included in this review. Post hoc analyses applicable to a broad audience were also included. Additional resources included product labeling.
Dosing and Administration
IDegLira is available in a 3-mL prefilled pen for once-daily subcutaneous injection, with a concentration of 100 U of degludec and 3.6 mg of liraglutide per mL. 10 It is indicated in patients who are inadequately controlled on <50 U of basal insulin or up to 1.8 mg of liraglutide daily. 10 To convert patients to IDegLira, liraglutide or basal insulin should be discontinued prior to its initiation. 10 IDegLira can then be administered the following day at the selected dosing time. There are no studies in patients previously uncontrolled on weekly GLP-1 RAs, so if a transition to IDegLira from these agents is warranted, individual kinetics should be considered and IDegLira initiation delayed until the next scheduled dose. Some clinicians may select to transition patients already taking both a basal insulin and a GLP-1 RA if these doses are within the indicated range for the product; similar transition strategies should be implemented in this scenario. The dosing and titration of IDegLira is guided by U of insulin degludec. The device can deliver doses ranging from 10 to 50 U in increments as small as 1 U of insulin degludec and 0.036 mg of liraglutide and can be titrated up or down by 2 U every 3 to 4 days until fasting plasma glucose (FPG) goal is reached. 10 In the DUAL-VI trial, titrating IDegLira once or twice weekly resulted in similar A1C reductions (−2.01% vs −2.02%) and patients achieving A1C <7% (90% for both); however, more patients in the twice-weekly group experienced confirmed hypoglycemia (8.6% vs 23.8%). In patients at high risk of hypoglycemia or hypoglycemia unawareness, a once-weekly titration may be preferred. Rates of all other AEs were similar. 11 Patients should be started on the minimum suggested dose of 16 U (0.58 mg liraglutide) and titrated up to a maximum dose of 50 U (1.8 mg liraglutide). 10 If adequate glycemic control is not reached in this dose range, other adjustments in the diabetes regimen or alternative medication options should be explored.
Pharmacology and Pharmacokinetics
Insulin degludec is the longest-acting basal insulin currently approved by the FDA. The half-life is 25 hours, resulting in a longer time (about 2-3 days) to reach steady state compared with other long-acting insulins.
10,12 The 24-hour exposure to insulin degludec is flat and stable, with no discernible peak effect throughout the day.
10,12 Duration of action is expected to be beyond 42 hours in patients with T2DM. Insulin was detectable at 120 hours (the last assessed measurement) after the sixth daily dose in a pharmacodynamic study. 12 Despite initial concern that the long duration of action would result in insulin stacking and hypoglycemia with daily dosing, a study comparing administration of insulin degludec with alternating 8-and 40-hour dose intervals with once-daily degludec and glargine demonstrated similar efficacy and safety between the 3 regimens. 13 No statistically significant difference between the groups was detected for overall, severe, or nocturnal hypoglycemia. 13 This supports insulin degludec as a safe and potentially desirable option for patients who are unable to take their dose at a regular time each day.
Liraglutide is an acylated long-acting GLP-1 RA that acts in a glucose-dependent manner to stimulate insulin secretion, inhibit glucagon secretion, delay gastric emptying, and suppress appetite.
14 Additionally, in mice, liraglutide has demonstrated the ability to increase β-cell mass. 15 The maximum concentration after a single dose occurs between 9 and 12 hours, and it has an elimination half-life of 11 to 15 hours. 14 In a study designed to evaluate the pharmacokinetic and glycemic effects of the combination product and compare it with those of the individual components, participants received single doses of either 17 dose steps (17 U insulin degludec/0.6 mg liraglutide) of IDegLira or 17 U of insulin degludec and 0.6 mg of liraglutide as separate agents administered at the same time. 16 Exposure to insulin degludec was similar with both formulations, whereas liraglutide exposure was higher with the individual agent compared with IDegLira, though it still met criteria for equivalence. 16 Ultimately, investigators concluded that the pharmacokinetic properties of IDegLira preserved those seen with the individual agents.
16

Clinical Trial Efficacy
The clinical safety and efficacy of IDegLira in patients previously uncontrolled on oral AHAs alone, oral AHAs and GLP-1 RAs, and oral AHAs and basal insulin were evaluated in the DUAL clinical trial program. Clinical trials are summarized in Table 1 .
Add-on to Oral AHAs
The DUAL-I trial evaluated IDegLira compared to insulin degludec and liraglutide alone in 1663 insulin-naïve patients previously receiving metformin with or without pioglitazone. Patients were randomized to receive liraglutide titrated to 1.8 mg daily, insulin degludec or IDegLira titrated based on FPG. At 26 weeks, the mean dose of IDegLira was 38 dose steps (1.4 mg liraglutide) compared with 53 U of insulin degludec and 1.8 mg liraglutide. A1C was reduced by 1.9% with IDegLira, which was noninferior to insulin degludec (−1.4%, P < 0.0001) and superior to liraglutide (−1.3%, P < 0.0001). IDegLira and insulin degludec yielded similar reductions in FPG (−64.8 mg/dL), which were significantly greater than that with liraglutide alone (−32.4 mg/dL). However, IDegLira had greater reductions in self-monitored postprandial plasma glucose Metformin ± Pioglitazone
(DUAL-I ext) 20 1660 52 (PPG) than insulin degludec and reductions comparable with that of liraglutide. 17 The effects on PPG were confirmed in a substudy, in which PPG increment decreased by 15.7 mg/dL with IDegLira, 3.1 mg/dL with insulin degludec (P = 0.0023), and 14.1 mg/dL with liraglutide (P = 0.7) following a standardized meal. 18 There was weight loss with IDegLira (−0.5 kg) and liraglutide (−3.0 kg), whereas weight gain was seen with insulin degludec (+1.6 kg); P <0.0001 for both comparisons. 17 Significant differences in A1C, FPG, and body weight became apparent within the first 12 weeks of therapy.
19 A 26-week extension of DUAL-I showed that reductions in A1C and FPG as well as changes in body weight were maintained for 1 year. Over the extension period, insulin degludec doses continued to increase to a mean of 62 U daily, whereas the mean dose of IDegLira increased minimally to 39 dose steps daily. 20 A post hoc analysis showed greater A1C reductions in patients with higher baseline A1C values. Patients with a baseline A1C >9% experienced mean A1C reductions of 2.5%. Patients receiving pioglitazone therapy had more significant A1C reductions (−2.1%) than those not receiving pioglitazone (−1.8%; P = 0.02). IDegLira had superior A1C reductions compared with insulin degludec and liraglutide regardless of baseline A1C, body mass index (BMI), and duration of diabetes. 21 The use of IDegLira as add-on therapy to a sulfonylurea (SU) with or without metformin was compared with placebo in the DUAL-IV trial. After 26 weeks, baseline A1C of 7.9% decreased to 6.4% with IDegLira and 7.4% with placebo (P < 0.001). IDegLira led to FPG reductions that were significantly greater than that with placebo (−48.8 vs 5.5 mg/dL; P < 0.001). Body weight increased by 0.5 kg with IDegLira and decreased by 1 kg with placebo (P < 0.001). 22 The results of the DUAL-I and DUAL-IV trials suggest a benefit in A1C and FPG lowering when compared with placebo and liraglutide therapy and similar benefit to insulin degludec alone when used as add-on to oral AHAs. Depending on baseline therapy, IDegLira appears to be relatively weight neutral, which may be a benefit when compared with weight gain seen with insulin degludec. The baseline therapies used in these trials are older therapies and, therefore, may not fully apply to patients currently uncontrolled on newer treatment options. Future trials adding IDegLira to and comparing IDegLira with newer oral therapies would be beneficial.
Use in Patients Receiving a GLP-1 RA
DUAL-III studied the effect of IDegLira in insulin-naïve patients with T2DM uncontrolled on metformin and a GLP-1 RA (liraglutide daily or exenatide twice daily) with or without pioglitazone or SU. A total of 438 patients were randomized to receive IDegLira 16 dose steps titrated twice weekly to a target FPG of 72 to 90 mg/dL or to continue on previous therapy. A1C and FPG decreased significantly in patients receiving IDegLira compared with those who continued GLP-1 therapy (A1C: −1.3% vs −0.3%; FPG: −63.6 vs −10.8 mg/dL; P < 0.001). In all, 75% of patients receiving IDegLira reached an A1C <7% from a mean baseline A1C of 7.8%, compared with 36% who remained on unchanged therapy (P < 0.001). On switching from GLP-1 therapy to IDegLira, there was no worsening in glycemic control during the titration period. Weight increased by 2 kg with IDegLira but decreased by 0.8 kg in the unchanged cohort (P < 0.001). Weight gain was higher in patients receiving a concomitant SU. 23 Although this study suggests benefit of switching to IDegLira, it does not use an active comparator. Studies comparing IDegLira to basal insulin would better guide treatment selection in this patient population.
Use in Patients Receiving Basal Insulin
Two studies, DUAL-II and DUAL-V, evaluated the efficacy and safety of IDegLira in patients previously receiving basal insulin. DUAL-II included 413 patients previously uncontrolled on metformin and basal insulin with or without SU or glinide. All AHAs except metformin were discontinued, and patients received either insulin degludec 16 U or IDegLira 16 dose steps daily. Both were titrated biweekly based on FPG to a maximum of 50 U or 50 dose steps. After 26 weeks, mean doses of insulin degludec were similar (45 U/dose step), and A1C was reduced by 1.9% with IDegLira and 0.9% with insulin degludec (P < 0.0001). IDegLira significantly improved FPG (−63 vs 46.8 mg/dL; P = 0.0019) and body weight (−2.7 vs 0.0 kg; P < 0.0001) when compared with insulin degludec. 24 Similar to DUAL-I, significant differences were seen within 12 weeks of starting therapy. 19 A post hoc analyses showed that A1C reductions were significantly greater with IDegLira regardless of baseline A1C, BMI, duration of diabetes, and baseline insulin dose with 1 exception. Patients with A1C ≤7.5% saw similar reductions with IDegLira and insulin degludec, but this represented only 11 patients-6 receiving IDegLira and 5 receiving insulin degludec. 21 Although the study indicates that IDegLira is superior to insulin degludec, it was only compared with a maximum dose of 50 U, which is not current practice. DUAL-V included 557 patients previously uncontrolled on metformin and insulin glargine and randomized them to receive IDegLira or continue on insulin glargine titrated twice weekly based on FPG. In contrast to DUAL-II, there was no maximum dose for insulin glargine, and the mean dose at 26 weeks was 66 U daily. IDegLira was titrated to 50 dose steps, with a mean dose of 41 dose steps. IDegLira significantly reduced A1C compared with insulin glargine (−1.8% vs 1.1%; P < 0.001) at 26 weeks. Reductions in FPG were similar between the 2 groups. Body weight was reduced by 1.4 kg with IDegLira and increased by 1.8 kg with insulin glargine (P < 0.001). 25 The DUAL-II and DUAL-V studies suggest that IDegLira provides additional glycemic control with weight loss when compared with titrating basal insulin. Limitations of these studies include the maximum basal insulin dose used in DUAL-II and the high doses used in DUAL-V. Some patients receiving higher doses of insulin glargine may have benefitted from agents providing postprandial coverage, including bolus insulin. Additional studies comparing rapid-acting insulin and IDegLira would provide additional guidance in this clinical setting.
Safety
AEs reported in the DUAL clinical trials are summarized in Table 2 . The most common treatment-emergent AEs were headache, nasopharyngitis, upper-respiratory infections, and gastrointestinal (GI) disorders. Most were considered mild to moderate and unlikely to be related to treatment. 17, 20, [22] [23] [24] [25] Serious AEs occurred in 2.3% to 5.9% of patients receiving IDegLira. 17, [23] [24] [25] The rate of serious AEs in DUAL IV appears to be higher than that in other trials; however, this is related to 11 events occurring in 2 patients, and they were all deemed unlikely to be related to IDegLira. 22 Rates of serious AEs with IDegLira were comparable with those of insulin degludec and liraglutide 17,23-25 but higher than that for placebo. 22 When compared with the individual components, more patients withdrew from treatment as a result of AEs with liraglutide than with IDegLira or insulin degludec alone. Withdrawals were primarily related to GI-associated events during treatment initiation.
17,20
Hypoglycemia
All studies defined confirmed hypoglycemia as a selfmonitored blood glucose <56 mg/dL or if patient required assistance, which was also considered severe. Nocturnal hypoglycemia was defined as events that occurred between 12:00 am and 5:59 am. Table 3 provides a summary of hypoglycemia occurring in clinical trials. When added to oral AHAs, IDegLira resulted in hypoglycemia in 32% to 42% of patients. 17 Hypoglycemia with IDegLira was significantly lower than with insulin degludec but higher than with GLP-1 RA therapy and placebo. 17, 20, 22 In patients previously receiving insulin, hypoglycemia occurred in 23% to 28% of patients receiving IDegLira, which was similar to that for insulin degludec but lower than that for insulin glargine (49%). 24, 25 In all trials, rates of severe hypoglycemia were low and less than that with insulin degludec alone. 17, 20, [22] [23] [24] [25] Nocturnal hypoglycemia was greater in patients receiving insulin glargine compared with IDegLira. 25 Hypoglycemia was more frequent in patients receiving a concomitant SU. 23 
GI-Related Adverse Effects
Nausea occurred in 3% to 10% of patients receiving IDegLira, was more frequent in the first 10 weeks of therapy, and subsided after that time. 17, [23] [24] [25] Rates of nausea were lower with IDegLira than with liraglutide alone but higher than that with insulin degludec or insulin glargine. 17, 24, 25 Mean lipase and amylase levels increased by 11 to 16.6 U/L and 6.7 to 10.7 U/L, respectively, in patients receiving IDegLira. These increases were similar to increases in patients receiving liraglutide alone. Despite these changes, no cases of pancreatitis related to IDegLira were confirmed by the adjudication committees of the DUAL clinical trials. 17, [22] [23] [24] [25] These trials excluded patients with a history of pancreatitis, so caution should be used when using any GLP-1 RA in patients with this history.
Therapeutic Considerations
IDegLira demonstrated benefit in glycemic control when used in patients previously uncontrolled on oral AHAs alone, including metformin, SUs, and pioglitazone as well as on oral AHAs combined with either a GLP-1 RA or basal insulin. Based on mean A1C reductions of 1.3% to 1.9% seen in clinical trials and greater reductions seen with higher A1C levels, patients with A1C <10% would likely benefit from the addition or substitution of IDegLira. Patients with A1C >10% would likely not reach A1C goal with IDegLira alone. Based on ADA and AACE guidelines, patients uncontrolled on oral AHAs may receive treatment with GLP-1 RA or insulin. 7, 8 The combination IDegLira resulted in significant A1C reductions compared with either individual component as well as less hypoglycemia and less weight gain when compared with basal insulin alone and less GI upset than with liraglutide alone. However, liraglutide alone resulted in greater weight loss and less hypoglycemia, which may make it a better option for patients if they are likely to reach A1C goal with this therapy. The use of IDegLira in patients receiving only oral AHAs should be reserved for patients unlikely to reach glycemic goals with a GLP-1 RA (A1C >9%) alone to avoid hypoglycemia and weight gain. Additional studies that include patients on oral AHAs with higher A1C values (>9%) would provide guidance on starting a GLP-1 RA, basal insulin, or combination.
For patients uncontrolled on oral AHAs and a GLP-1 RA, basal insulin is likely the next step in therapy. 7, 8 IDegLira provides additional glycemic control without additional injections. Patients not reaching glycemic goals on oral AHAs and submaximal doses of a GLP-1 RA who are unable to titrate therapy as a result of GI adverse events may also benefit from IDegLira, which may reduce A1C without additional GI AEs. In patients uncontrolled on basal insulin, the switch to IDegLira may provide improvement in A1C and weight with minimal hypoglycemia. Studies only compared 23 Buse et al, 2014
(DUAL-II) 24 Lingvay 17 Gough et al, 2015 (DUAL-I ext) 20 Rodbard et al, 2017 (DUAL-IV) 22 Linjawi et al, 2017 (DUAL-III) 23 Buse et al, 2014 (DUAL-II) 24 Lingvay et al, 2016 (DUAL-V) IDegLira with continued titration of basal insulin, which may have resulted in increased rates of hypoglycemia. Studies comparing IDegLira with bolus insulin in patients on basal insulin would provide additional clinically relevant data. Careful consideration of current therapy, risk of hypoglycemia, body weight, BMI, and A1C reduction needed to reach goals should guide recommendations for IDegLira. The combination of these 2 medications in 1 device provides some benefits to patients in that it reduces the number of injections required compared with taking the medication separately, which may improve adherence. Furthermore, use of IDegLira will result in lower costs for patients compared with using both agents individually, including lower costs associated with needle purchases. Patients who are covered by commercial or private insurances can obtain copay assistance, which will further offset costs. A cost-effectiveness study showed that the use of IDegLira was more cost-effective than intensifying basal insulin, or adding bolus insulin or liraglutide to basal insulin primarily because of the larger decrease in A1C. This study was based in Sweden and used historical data because direct comparison studies are not available for all these regimens; therefore, the results may not be globally applicable. 26 A drawback to using a fixeddose combination is that medications cannot be individually titrated. This is also a concern for IDegLira, but studies did not show that AEs limited titration. In fact, GI AEs were lower with the combination product than with GLP-1 RA therapy alone, likely because of a slower titration schedule. Hypoglycemia associated with increased insulin dose would be most likely to restrict dose titration of IDegLira.
Summary
IDegLira offers clinicians another reasonable option for advancing therapy in select patients with T2DM not controlled on basal insulin or a GLP-1 RA with or without other AHAs. Use of the combination agent offers advantages of improved efficacy compared with either agent alone, less hypoglycemia and improved weight profile compared with basal insulin, and better GI tolerability compared with dosing titration recommendations of liraglutide. Use of the combination product will also result in cost savings and less frequent daily injections compared with use of the components separately or a basalbolus insulin regimen. Utility in patients with baseline A1Cs higher than 9%, on prandial insulin, or requiring more than 50 U of basal insulin daily is likely limited; further studies are warranted to guide therapy in these scenarios.
